Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Agilent Technologies; ImmunID; GeneNews; and More

NEW YORK (GenomeWeb) – Agilent Technologies announced this week that it will pay a quarterly dividend of 11.5 cents per share of common stock on April 27 to all shareholders of record as of the close of business on April 5.

ImmunID said this week that it has incorporated a US subsidiary called ImmunID Inc. The new business unit will support the development of company's activities in the US and will facilitate US patient access to its ImmunTraCkeR molecular diagnostic assay.

GeneNews announced this week that the Toronto Stock Exchange has extended its remedial review process for 58 days to allow the company additional time to demonstrate compliance with the continued listing requirements. GeneNews has made progress over the past several weeks toward restructuring its operations, the company said, and this may have a positive impact on its ability to demonstrate compliance with the listing requirements. The TSX currently intends to make a decision regarding the firm's eligibility for continued listing by May 13.

Marina Biotech announced this week that is has entered into a license agreement to use its Smarticles and DiLa2 platforms in the development of an undisclosed genome editing technology. The company declined to name its partner. Under terms of the agreement, Marina could receive up to $40 million in success-based milestones.

Genomic Vision said this week that it has obtained NF EN ISO 13485:2012 quality assurance certification for its manufacturing, sales, and related services such as installation and maintenance activities relating to in vitro diagnostic instruments and kits used in molecular genetic testing for human pathologies.

Ubiquitome this week launched a crowdfunding campaign on the Indiegogo platform to accelerate the manufacture of an FDA-authorized Zika mobile molecular diagnostic test to be available to US citizens before the Summer Olympics in Rio de Janeiro. The company would like to fund a test that would be available from existing laboratories, as well as on Ubiquitome’s mobile molecular testing technology.

DermTech announced this week that it has completed payment contracts with third-party payor networks MultiPlan and FedMed for its Pigmented Lesion Assay.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.